|
We are pleased to announce that, effective January 5, 2026, CIMERLI® will be offered at a substantially lower Wholesale Acquisition Cost (WAC). This price reduction underscores Sandoz’s ongoing commitment to enhancing patient affordability and access to therapy, while demonstrating responsiveness to evolving market dynamics.
Price Reduction
CIMERLI® WAC will be available at a 90% discount relative to Lucentis WAC. The NDC and Q codes remain unchanged; it is the same product, available in the same two dosage strengths. droAdditional details are provided below:
|